Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Daisuke Kato"'
Autor:
Musashi Fukuda, Yoshiya Tanaka, Tsutomu Takeuchi, Mitsuhiro Rokuda, Yuichiro Kaneko, Daisuke Kato, Hiroyuki Izutsu
Publikováno v:
Modern Rheumatology. 32:708-717
Objective To analyse serious infection (SI) and herpes zoster-related disease (HZD) during long-term treatment of rheumatoid arthritis with the oral Janus kinase inhibitor, peficitinib (ASP015K). Methods This was a post hoc analysis of pooled data fr
Autor:
Yoshiya Tanaka, Yuichiro Kaneko, Mitsuhiro Rokuda, Hiroyuki Izutsu, Musashi Fukuda, Neil M. Schultz, Daisuke Kato, Tsutomu Takeuchi
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-14 (2021)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety in the treatment of patients with rheumatoid arthritis (RA). This study evaluated the effect of peficitinib on patient- and physician-reported
Autor:
Soyoung Kim, Yoshiya Tanaka, Justyna Chorąży, Hiroyuki Okumura, Daisuke Kato, Julie Dorey, Neil M. Schultz, Piotr Wojciechowski
Publikováno v:
Rheumatology and Therapy
Introduction Peficitinib, a Janus kinase (JAK) inhibitor, is approved for clinical use in Japan, Korea, and Taiwan, but head-to-head comparisons versus other JAK inhibitors are lacking. We indirectly compared peficitinib, tofacitinib, and baricitinib
Publikováno v:
Journal of Hard Tissue Biology. 30:1-6
Publikováno v:
Lower Urinary Tract Symptoms
Objectives The aim of this post hoc analysis from the Japanese mirabegron surveillance program was to investigate the safety and effectiveness of mirabegron in male patients with overactive bladder (OAB) symptoms with/without concomitant benign prost
Publikováno v:
Lower Urinary Tract Symptoms
Objective This analysis was conducted to investigate the cardiovascular (CV) safety outcomes from the MILAI II study. MILAI II was conducted to evaluate the long‐term safety and efficacy of antimuscarinic add‐on therapy to mirabegron over 52 week
Autor:
Musashi Fukuda, Daisuke Miyatake, Yuichiro Kaneko, Yoshiya Tanaka, Tsutomu Takeuchi, Daisuke Kato
Publikováno v:
Modern rheumatology. 32(4)
Objectives To evaluate peficitinib efficacy and safety in Asian patients with rheumatoid arthritis (RA), stratified by age (≥20– Methods Efficacy data from two Phase 3 studies were analysed. Safety data from one Phase 2, two Phase 3, and one open
Publikováno v:
Neurological Sciences. 41:1973-1975
Autor:
Zhongtian Guo, Shouta Sugio, Hideto Yamada, Ako Ikegami, Akari Hashimoto, Kana Ozaki, Tsuyako Tatematsu, Midori Shibushita, Daisuke Kato, Andrew J. Moorhouse, Hiroaki Wake, Koichiro Haruwaka
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-19 (2020)
Scientific Reports
Scientific Reports
Maternal infection or inflammation causes abnormalities in brain development associated with subsequent cognitive impairment and in an increased susceptibility to schizophrenia and autism spectrum disorders. Maternal immune activation (MIA) and incre
Autor:
Yuichiro Kaneko, Tsutomu Takeuchi, Yoshiya Tanaka, Musashi Fukuda, Hiroyuki Izutsu, Daisuke Kato, Mitsuhiro Rokuda
To evaluate the safety of peficitinib for the treatment of rheumatoid arthritis (RA) in Asian patients. Safety data from one Phase 2b, two Phase 3, and one open-label long-term extension study [data cut-off 31 May 2018] were pooled into Phase 3 studi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6462032c103d5cdc07b92771ac89545